----item----
version: 1
id: {92FAA5D5-5097-4DC1-89E7-4AA57934D2B9}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/06/11/3SBio raises HKK417bn in IPO
parent: {0C4E4294-FE7F-444B-9DB5-24F666F256E8}
name: 3SBio raises HKK417bn in IPO
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 120bb3c3-b7ab-49fb-b2ce-a5c0758215fc

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 30

3SBio raises HKK$4.17bn in IPO
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 28

3SBio raises HKK417bn in IPO
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2767

<p>China biotech form 3SBio, which delisted from Nasdaq in 2013, has raised HKK$4.17bn ($540m) through an initial public offering on the Hong Kong stock exchange. The shares were priced at HK$9.10 each. 3SBio offered 484.9 million new shares with further funds being raised by shareholder CITIC Private Equity which offered another 121.2 million shares.</p><p>3SBio's <a href="http://www.scripintelligence.com/business/Chinas-3SBio-lays-out-final-340m-go-private-proposal-339918" target="_new">delisting from Nasdaq</a> and privatization in 2013 were spearheaded by chairman and CEO Dr Jing Lou and CPEChina Fund, a China-focused private equity fund linked to CITIC, China's huge state-run investment conglomerate.</p><p>The company said the proceeds of the IPO would be spent as follows:</p><p>?45% of the net proceeds, or approximately HK$1.88bn,to expand its portfolio of pharmaceutical products in the company's focused therapeutic areas through selective acquisitions. The company is primarily interested in acquiring companies with mature product lines and first-to-market drugs, as well as companies with high innovation capabilities;</p><p>?15% of the net proceeds, or approximately HK$625.5m, to strengthen the sales and marketing of the products;</p><p>?15% of the net proceeds to fund capital expenditure projects to increase the company's production capabilities by constructing new production lines in anticipation of the expected increase in demand for the company's current products and the launch of product candidates;</p><p>?15% of the net proceeds, to fund the company's R&D projects, including in-house R&D projects and external collaboration projects. </p><p>?10% of the net proceeds, to supplement the company's working capital and for general corporate purposes.</p><p>3SBio's two core products are TPIAO &ndash; a recombinant human thrombopoietin to treat chemotherapy-induced thrombocytopenia and idiopathic thrombocytopenic purpura, and EPIAO &ndash; a human recombinant erythropoietin to treat anemia associated with chemotherapy or chronic kidney disease. "TPIAO, our proprietary product, is the only commercialized rhTPO product in the world," states 3SBio. "EPIAO leads the PRC rhEPO market with a market share of 43.6% by sales in 2013, more than the combined market shares of the next six largest competitors."</p><p>3SBio also claims to have a pipeline of 20 product candidates. "We have eight product candidates in nephrology, including three next-generation erythropoiesis-stimulating agents (ESAs). We have six product candidates in oncology, including three mAb therapeutics. We also have several product candidates that target auto-immune diseases with unmet treatment needs such as rheumatoid arthritis and refractory gout."</p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 357

<p>China biotech form 3SBio, which delisted from Nasdaq in 2013, has raised HKK$4.17bn ($540m) through an initial public offering on the Hong Kong stock exchange. The shares were priced at HK$9.10 each. 3SBio offered 484.9 million new shares with further funds being raised by shareholder CITIC Private Equity which offered another 121.2 million shares.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 28

3SBio raises HKK417bn in IPO
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150611T231514
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150611T231514
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150611T231514
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028967
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 30

3SBio raises HKK$4.17bn in IPO
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{20E0B55E-5592-4DBF-A9D4-58B471A17E67}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358823
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042401Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

120bb3c3-b7ab-49fb-b2ce-a5c0758215fc
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042401Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
